Literature DB >> 797494

The binding of drugs to plasma proteins from patients with poor renal function.

M M Reidenberg.   

Abstract

Plasma from patients with renal failure has decreased binding of many drugs. The decreased binding of anionic drugs is pronounced and is apparently due to occupation of protein binding sites by non-dialysable endogenous acidic compounds. Organic bases seem to bind normally, particularly if hypoproteinaemia or hypoalbuminaemia are not present. This modification of drug binding to plasma proteind from uraemic patients must be considered when plasma concentrations of acidic drugs are measured.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 797494     DOI: 10.2165/00003088-197601020-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  30 in total

1.  Serum albumin in uremia: a clinical investigation correlated with reversible uremia in dogs.

Authors:  R BAKER
Journal:  J Urol       Date:  1951-02       Impact factor: 7.450

2.  Trimethoprim-sulfamethoxazole: pharmacodynamic effects of urinary pH and impaired renal function. Studies in humans.

Authors:  W A Craig; C M Kunin
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

3.  Decreased drug binding by serum albumin during renal failure.

Authors:  D S Campion
Journal:  Toxicol Appl Pharmacol       Date:  1973-07       Impact factor: 4.219

4.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

Review 5.  Utility of clinical chemical determinations of drug concentrations in biological fluids.

Authors:  E S Vessell; G T Passananti
Journal:  Clin Chem       Date:  1971-09       Impact factor: 8.327

6.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia.

Authors:  I Odar-Cederlöf; P Lunde; F Sjöqvist
Journal:  Lancet       Date:  1970-10-17       Impact factor: 79.321

7.  Protein binding of drugs in plasma from patients with acute renal failure.

Authors:  F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

8.  The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

Authors:  D W Shoeman; D L Azarnoff
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

9.  Altered protein binding of diphenylhydamtoin in uremic plasma.

Authors:  M R Blum; S Riegelman; C E Becker
Journal:  N Engl J Med       Date:  1972-01-13       Impact factor: 91.245

10.  Kinetics of salicylate elimination by anephric patients.

Authors:  D T Lowenthal; W A Briggs; G Levy
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

View more
  32 in total

Review 1.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

3.  Effect of renal or hepatic dysfunction on neurotoxic convulsion induced by ranitidine in mice.

Authors:  M Shimokawa; K Yamamoto; J Kawakami; Y Sawada; T Iga
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

4.  Protein binding of enprofylline.

Authors:  K Tegnér; O Borgå; I Svensson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Propranolol disposition in renal failure.

Authors:  A J Wood; R E Vestal; C L Spannuth; W J Stone; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

6.  Haemodialysis does not affect the pharmacokinetics of nifedipine.

Authors:  H Martre; R Sari; A M Taburet; C Jacobs; E Singlas
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

Review 7.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 8.  Protein binding of cardiac glycosides in disease states.

Authors:  L Storstein
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

9.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

10.  The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment.

Authors:  J V St Peter; M E Brady; E F Foote; K A Dandekar; L Smaldone; J L Pykkonen; W F Keane; C E Halstenson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.